Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Clin Infect Dis. 2020 Jan 1;70(1):11-18. doi: 10.1093/cid/ciz169.
Unnecessary antibiotic use (AU) contributes to increased rates of Clostridioides difficile infection (CDI). The impact of antibiotic restriction on hospital-onset CDI (HO-CDI) has not been assessed in a large group of US acute care hospitals (ACHs).
We examined cross-sectional and temporal associations between rates of hospital-level AU and HO-CDI using data from 549 ACHs. HO-CDI was defined as a discharge with a secondary International Classification of Diseases, Ninth Revision, Clinical Modification code for CDI (008.45), and treatment with metronidazole or oral vancomycin > 3 days after admission. Analyses were performed using multivariable generalized estimating equation models adjusting for patient and hospital characteristics.
During 2006-2012, the unadjusted annual rates of HO-CDI and total AU were 7.3 per 10 000 patient-days (PD) (95% confidence interval [CI], 7.1-7.5) and 811 days of therapy (DOT)/1000 PD (95% CI, 803-820), respectively. In the cross-sectional analysis, for every 50 DOT/1000 PD increase in total AU, there was a 4.4% increase in HO-CDI. For every 10 DOT/1000 PD increase in use of third- and fourth-generation cephalosporins or carbapenems, there was a 2.1% and 2.9% increase in HO-CDI, respectively. In the time-series analysis, the 6 ACHs with a ≥30% decrease in total AU had a 33% decrease in HO-CDI (rate ratio, 0.67 [95% CI, .47-.96]); ACHs with a ≥20% decrease in fluoroquinolone or third- and fourth-generation cephalosporin use had a corresponding decrease in HO-CDI of 8% and 13%, respectively.
At an ecologic level, reductions in total AU, use of fluoroquinolones, and use of third- and fourth-generation cephalosporins were each associated with decreased HO-CDI rates.
不必要的抗生素使用(AU)会导致艰难梭菌感染(CDI)的发生率增加。抗生素限制对美国急性护理医院(ACH)中大量医院获得性 CDI(HO-CDI)的影响尚未得到评估。
我们使用来自 549 家 ACH 的数据,检查了医院层面 AU 率与 HO-CDI 的横断面和时间关联。HO-CDI 的定义是出院时具有次要国际疾病分类,第九修订版,临床修正代码为 CDI(008.45),并在入院后 3 天以上接受甲硝唑或口服万古霉素治疗。使用多变量广义估计方程模型进行分析,调整患者和医院特征。
在 2006-2012 年期间,未经调整的 HO-CDI 和总 AU 的年发生率分别为每 10000 个患者日(PD)7.3 例(95%置信区间 [CI],7.1-7.5)和 811 天治疗(DOT)/1000 PD(95%CI,803-820)。在横断面分析中,总 AU 每增加 50DOT/1000 PD,HO-CDI 增加 4.4%。第三代和第四代头孢菌素或碳青霉烯类药物每增加 10DOT/1000 PD,HO-CDI 分别增加 2.1%和 2.9%。在时间序列分析中,总 AU 减少≥30%的 6 家 ACH 的 HO-CDI 减少了 33%(率比,0.67 [95%CI,0.47-0.96]);氟喹诺酮类药物或第三代和第四代头孢菌素使用减少≥20%的 ACH,HO-CDI 相应减少 8%和 13%。
在生态水平上,总 AU 减少、氟喹诺酮类药物和第三代和第四代头孢菌素的使用减少均与 HO-CDI 发生率降低有关。